Anixa Biosciences Inc

Anixa Biosciences Inc a biotechnology company develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases The companys therapeutics programs include the development of a chimeric endocrine receptor Tcell technology a novel form of chimeric antigen receptor Tcell CART technology focusing on the treatment of ovarian cancer and the discovery and development of antiviral drug candidates for the treatment of COVID19 focused on inhibiting certain protein functions of the virus Its vaccine programs comprise the development of a vaccine against triple negative breast cancer and a preventative vaccine against ovarian cancer The company is also developing immunotherapy drugs against cancer It has a collaboration agreement with MolGenie GmbH to discover and develop antiviral drug candidates against COVID19 The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences Inc in October 2018 Anixa Biosciences Inc was incorporated in 1982 and is based in San Jose California